Finding early signs of dilated cardiomyopathy with AI and mobile screening
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial uses a smartphone app to screen first-degree relatives of people with dilated cardiomyopathy (DCM) for early signs of the condition. It aims to detect heart muscle weakness before symptoms start, so that treatment can begin sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must be a first-degree relative (parent, sibling, or child) of someone diagnosed with dilated cardiomyopathy (non-ischemic type)
- You must have access to a smartphone or a tablet with internet or cellular data
- You must not have already been told to have heart screening or been diagnosed with a weak heart muscle
- You must be able to provide verbal consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a heart MRI to measure details in people with dilated cardiomyopathy and reduced pumping strength. It aims to use these MRI findings to better predict your future heart risk and guide care.
This study uses heart MRI scans to predict who might develop dangerous heart rhythms. It's for people with certain types of non-ischemic heart disease who have already had an MRI with contrast.
This study tests a mobile health app to help African American women with overweight or obesity in specific DC and Maryland neighborhoods improve their heart health. Participants will use the app and wear a wrist device to track activity, with the goal of reducing heart disease risk.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
This study tests if an AI-powered system can help manage premature coronary artery disease in adults aged 18 to 45. It uses a smartphone app to support treatment and improve outcomes.
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
Hear when a new Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.